Article Text

Download PDFPDF

320 Urine tweak protein is a novel biomarker for resistant-to-treat lupus nephritis
  1. T Suttichet1,2,
  2. T Saetang3,
  3. S Anutrakulchai4,
  4. T Panaput5,
  5. J Wongchinsri6,
  6. S Chaishayanon6,
  7. B Satirapoj7,
  8. O Traitanon8,
  9. B Thinkhamrop9 and
  10. Y Avihingsanon1
  1. 1Faculty of Medicine- Chulalongkorn University, Department of Medicine, Bangkok, Thailand
  2. 2Center of Excellence in Immunology and Immune-mediated diseases- Chulalongkorn University, Department of Microbiology, Bangkok, Thailand
  3. 3Systems Biology Center- Faculty of Medicine- Chulalongkorn University, Research Affairs, Bangkok, Thailand
  4. 4Faculty of Medicine- Khon Kean University, Department of Medicine, Khon Kean, Thailand
  5. 5Khon Kean Regional Hospital, Department of Medicine, Khon Kaen, Thailand
  6. 6Nopparat Rajathani Hospital, Department of Medicine, Bangkok, Thailand
  7. 7Pramongkutklao School of Medicine, Department of Medicine, Bangkok, Thailand
  8. 8Faculty of Medicine- Thammasat University, Department of of Medicine, Pathumthani, Thailand
  9. 9Faculty of Public Health- Khon Kean University, Department of Biostatistics and Demography, Khon Kaen, Thailand


Background and aims Tumour necrosis factor-like weak inducer of apoptosis (TWEAK) is an inflammatory cytokine that processes via prolonged activation of the NF-κB pathway. TWEAK plays role in autoimmune diseases like lupus nephritis (LN). TWEAK soluble form and its receptor were found in active LN. We determined whether urinary TWEAK (uTWEAK) levels predict response to standard treatment in a multi-centre clinical trial of lupus patients.

Methods Urine samples were collected at baseline, 3 and 6 month of LN patients from a multi-centre randomized-controlled study ( ID#NCT01015456). The uTWEAK levels were measured with commercially available enzyme-linked immunosorbent assay (ELISA) kits.

Results All subjects (n=49) were biopsy-proven proliferative class III/IV LN. Median (IQR) patient’s age were 32 (29-36) years old. Urine protein creatinine ratio and serum creatinine were 6.32 (6.16–9.20) mg/mg and 0.80 (0.82–1.03) mg/dL. After 6 month treatment of either intravenous cyclophosphamide (IVCY) or mycophenolate sodium (MPS) and steroids, there were 32 responders and 13 non-responders. Baseline uTWEAK levels were higher in non-responder LN compared with responders LN. This was observed in both treatment either IVCY (n=25) or MPS (n=24) (175.50±36.97 vs 57.09±7.40 pg/mL; p=0.018 or 124.90±34.53 vs 55.69±14.22 pg/mL; p=0.038). The area under the ROC curve to predict response to treatment was 0.79 (95% CI=0.64–0.94). The cut-off level of 94.0 pg/dL predict resistant-to-treat at sensitivity and specificity of 64 and 85 percent, respectively.

Conclusions uTWEAK may be a biomarker that guide treatment of lupus nephritis patients. Targeting TWEAK protein in active lupus nephritis is an interesting choice of therapy.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.